|
Melinta Therapeutics, Inc. (CEMP) |
|
|
|
CEMP's Revenue Growth by Quarter and Year
Melinta Therapeutics,'s Revenue results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
CEMP Revenue (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
IV Quarter |
December |
-
|
35.49
|
0.00
|
7.95
|
III Quarter |
September |
15.87
|
34.08
|
1.72
|
3.97
|
II Quarter |
June |
15.96
|
12.02
|
0.86
|
3.42
|
I Quarter |
March |
14.08
|
14.84
|
4.87
|
2.68
|
FY |
|
45.91
|
96.43
|
7.45
|
18.02
|
CEMP Revenue third quarter 2019 Y/Y Growth Comment |
Melinta Therapeutics, Inc. reported drop in Revenue in the third quarter 2019 by -53.43% to $ 15.87 millions, from the same quarter in 2018. The fall in the third quarter 2019 Melinta Therapeutics, Inc.'s Revenue compares unfavorably to the Company's average Revenue doubling of 204.95%.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 202 other companies have achieved higher Revenue growth. While Melinta Therapeutics, Inc.' s Revenue meltdown of -53.43% ranks overall at the positon no. 3839 in the third quarter 2019.
|
CEMP Revenue ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
- |
- |
37.31 % |
III Quarter |
September |
-53.43 % |
1881.4 % |
-56.68 % |
58.8 % |
II Quarter |
June |
32.78 % |
1297.67 % |
-74.85 % |
-32.28 % |
I Quarter |
March |
-5.12 % |
204.72 % |
81.72 % |
-80.8 % |
FY |
|
- |
1194.36 % |
-58.66 % |
-33.99 % |
CEMP Revenue (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
4.14 % |
- |
100.25 % |
III Quarter |
September |
-0.56 % |
183.53 % |
100 % |
16.08 % |
II Quarter |
June |
13.35 % |
-19 % |
-82.34 % |
27.61 % |
I Quarter |
March |
-60.33 % |
- |
-38.74 % |
-53.71 % |
FY (Year on Year) |
|
- |
1194.36 % |
-58.66 % |
-33.99 % |
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
1884.74 % |
204.95 % |
-100 % |
(Sep 30 2018) |
|
(Dec 31 2017) |
|
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
1884.74 % |
204.95 % |
-100 % |
(Sep 30 2018) |
|
(Dec 31 2017) |
|
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Melinta Therapeutics,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
465.3 % |
34.45 % |
-100 % |
(Mar 31 2015) |
|
|
CEMP's III. Quarter Q/Q Revenue Comment |
In the III. Quarter 2019 Melinta Therapeutics, Inc. reported decrease in Revenue sequentially by -0.56% to $ 15.87 millions, from $ 15.96 millions released in the previous reporting period.
Some seasonal factors which usually elevate III. Quarter 2019 performance, could not recover the III. Quarter for the Melinta Therapeutics, Inc., Kabir Kadam , Major Pharmaceutical Preparations industry expert situated in Nagpur pointed out, he voiced some caution conserning Melinta Therapeutics,'s direction, he detected further difficulties onward for Melinta Therapeutics, and continued that average sequential Revenue growth is at 34.45% for Melinta Therapeutics,.
Within Major Pharmaceutical Preparations industry 153 other companies have achieved higher Revenue quarter on quarter growth. While Melinta Therapeutics,'s Revenue growth quarter on quarter, overall rank is 2456. |
|
|
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
465.3 % |
34.45 % |
-100 % |
(Mar 31 2015) |
|
|
CEMP's III. Quarter Q/Q Revenue Comment |
In the III. Quarter 2019 Melinta Therapeutics, Inc. disclosed decrease in Revenue from the second quarter by -0.56% to $ 15.87 millions, from $ 15.96 millions declared a quarter before.
Even cyclical circumstance were not able to salvage the III. Quarter for the Melinta Therapeutics, Inc., Kabir Kadam , Major Pharmaceutical Preparations industry expert situated in Nagpur said and mentioned that average sequential Revenue growth is at 34.45% for CEMP.
Within Major Pharmaceutical Preparations industry 153 other companies have achieved higher Revenue quarter on quarter growth. While Melinta Therapeutics,'s Revenue growth quarter on quarter, overall rank is 2456. |
|
Melinta Therapeutics,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending (Sep 30 2019) |
12 Months Ending (Jun 30 2019) |
12 Months Ending (Mar 31 2019) |
12 Months Ending (Dec 31 2018) |
12 Months Ending (Sep 30 2018) |
Cumulative Revenue 12 Months Ending |
$ 81.40 |
$ 99.61 |
$ 95.67 |
$ 96.43 |
$ 0.00 |
Y / Y Revenue Growth (TTM) |
- |
452.88 % |
- |
- |
- |
Year on Year Revenue Growth Overall
Ranking |
# 769 |
# 608 |
# 0 |
# 0 |
# 0 |
Seqeuential Revenue Change (TTM) |
-18.28 % |
4.11 % |
-0.79 % |
- |
- |
Seq. Revenue Growth (TTM) Overall
Ranking |
# 2449 |
# 88 |
# 0 |
# 0 |
# 0 |
Cumulative Revenue growth
Comment |
In the Healthcare sector 171 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 608 to 769. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
452.88 % |
67.33 % |
-50.81 % |
|
|
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
255.67 % |
34.79 % |
-50.81 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 140 |
Sector |
# 338 |
S&P 500 |
# 2449 |
|
Cumulative Revenue growth
Comment |
In the Healthcare sector 171 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 608 to 769. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
452.88 % |
67.33 % |
-50.81 % |
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
255.67 % |
34.79 % |
-50.81 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 140 |
Sector |
# 338 |
S&P 500 |
# 2449 |
|